0001104659-24-086529.txt : 20240807 0001104659-24-086529.hdr.sgml : 20240807 20240807070019 ACCESSION NUMBER: 0001104659-24-086529 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20240807 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20240807 DATE AS OF CHANGE: 20240807 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Liquidia Corp CENTRAL INDEX KEY: 0001819576 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 851710962 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-39724 FILM NUMBER: 241181358 BUSINESS ADDRESS: STREET 1: 419 DAVIS DRIVE, SUITE 100 CITY: MORRISVILLE STATE: NC ZIP: 27560 BUSINESS PHONE: 919.328.4400 MAIL ADDRESS: STREET 1: 419 DAVIS DRIVE, SUITE 100 CITY: MORRISVILLE STATE: NC ZIP: 27560 8-K 1 tm2420885d1_8k.htm FORM 8-K
false 0001819576 0001819576 2024-08-07 2024-08-07 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): August 7, 2024

 

LIQUIDIA CORPORATION
(Exact name of registrant as specified in its charter)
     
Delaware 001-39724 85-1710962

(State or other jurisdiction

of incorporation)

(Commission

File Number)

(IRS Employer

Identification No.)

     
419 Davis Drive, Suite 100, Morrisville, North Carolina 27560
(Address of principal executive offices) (Zip Code)

  

Registrant’s telephone number, including area code: (919) 328-4400

(Former name or former address, if changed since last report.)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class Trading Symbol(s) Name of each exchange on which registered
Common stock LQDA The Nasdaq Stock Market LLC

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company ¨

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

 

 

 

 

 

 

Item 2.02 Results of Operations and Financial Condition.

 

On August 7, 2024, Liquidia Corporation, a Delaware corporation, issued a press release announcing its financial results for the quarter ended June 30, 2024, and also provided a corporate update. A copy of the press release is furnished herewith as Exhibit 99.1.*

 

Item 9.01 Financial Statements and Exhibits.

 

(d)

 

Exhibit
No.		   Exhibit
99.1   Press Release of Liquidia Corporation, dated August 7, 2024.
104   Cover Page Interactive Data File (embedded within the Inline XBRL document).

 

* The information in Item 2.02 of this Form 8-K shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.

 

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

August 7, 2024 Liquidia Corporation
   
  By: /s/ Michael Kaseta
    Name: Michael Kaseta
    Title: Chief Financial Officer and Chief Operating Officer

 

 

 

 EX-99.1 2 tm2420885d1_ex99-1.htm EXHIBIT 99.1

 

Exhibit 99.1

 

Liquidia Corporation Reports Second Quarter 2024 Financial Results and
Provides Corporate Update

 

MORRISVILLE, N.C., August 7, 2024 -- Liquidia Corporation (NASDAQ: LQDA), a biopharmaceutical company developing innovative therapies for patients with rare cardiopulmonary disease, today reported financial results for the second quarter ended June 30, 2024. The company will host a webcast at 8:30 a.m. ET on August 7, 2024 to discuss the financial results and provide a corporate update.

 

Dr. Roger Jeffs, Liquidia’s Chief Executive Officer, said: “We continue to face no legal impediments for the FDA approval of YUTREPIA for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), and our commercial team stands ready to launch YUTREPIA contingent on the FDA’s final approval. If approved, we firmly believe that the ease of administration and broad dosage spectrum of YUTREPIA will drive the treatment to become the preferred prostacyclin therapy of choice.”

 

Corporate Updates

 

Progressed litigation, maintaining a clear legal path to full approval of YUTREPIA

 

On May 31, Judge Andrews of the U.S. District Court for the District of Delaware denied the motion for preliminary injunction filed by United Therapeutics (UTHR) in its lawsuit alleging that YUTREPIA infringes U.S. Patent No. 11,826,327 (‘327 patent).

 

In addition, on March 29, the U.S. District Court for the District of Columbia has denied motions for a temporary restraining order and preliminary injunction requested by UTHR in its suit against the U.S. Food and Drug Administration (FDA). On May 7, both Liquidia and FDA filed motions to dismiss UTHR’s complaint.

 

While both lawsuits are continuing forward, these rulings reinforce the clear legal path for FDA to issue a final decision on the amended New Drug Application (NDA) for YUTREPIA for the treatment of both PAH and PH-ILD.

 

Progressed clinical studies in YUTREPIA and presented new posters at the World Symposia on Pulmonary Hypertension

 

During the World Symposia on Pulmonary Hypertension in Barcelona this summer, Liquidia presented two live thematic poster sessions and five encore presentations covering the company’s investigational products, YUTREPIA™ (treprostinil) inhalation powder and L606 (liposomal treprostinil) inhalation suspension. The two new posters entitled: “Exploratory Efficacy Analysis of INSPIRE Open Label Extension Study with Inhaled Treprostinil (YUTREPIA™)” and “High Resolution Computed Tomography (HRCT) Chest Scans to Examine the Association Between Regional Drug Deposition of LIQ861 (YUTREPIA™) and Vasodilation in PH-ILD Population,” along with the five encore presentations, can be found on the Publications section of Liquidia’s website.

 

 

 

 

Progressed L606 in clinic and presented summary of safety and dosing poster at the American Thoracic Society 2024 International Conference (ATS)

 

In May at the ATS Conference in San Diego, Liquidia presented data related to the investigational use of L606 (liposomal treprostinil) inhalation suspension in patients with pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).

 

The Phase 3, 2-part, open-label, multicenter study aims to demonstrate the safety and tolerability of L606 in patients with PAH or PH-ILD in the short-term and long-term. The trial is enrolling patients in two groups, a transition group and a naïve group. The transition group is comprised of participants with PAH or PH-ILD who transitioned from nebulized Tyvaso or Tyvaso DPI to L606. The naïve group is comprised of participants with PAH who have not previously received treprostinil therapy and added L606 to no more than two non-prostacyclin oral therapies.

 

Second Quarter 2024 Financial Results

 

Cash and cash equivalents totaled $133.1 million as of June 30, 2024, compared to $83.7 million as of December 31, 2023.

 

Revenue was $3.7 million for the three months ended June 30, 2024, compared to $4.8 million for the three months ended June 30, 2023. Revenue related primarily to our promotion agreement with Sandoz pursuant to which we share profits from the sale of Treprostinil Injection in the United States (the Promotion Agreement). The decrease of $1.1 million was primarily due to the impact of lower sales quantities in the current year as compared to the same period in the prior year.

 

Cost of revenue was $1.5 million for the three months ended June 30, 2024, compared to $0.7 million for the three months ended June 30, 2023. Cost of revenue related to the Promotion Agreement as noted above. The increase from the prior year was primarily due to our sales force expansion during the fourth quarter of 2023.

 

Research and development expenses were $9.4 million for the three months ended June 30, 2024, compared to $17.7 million for the three months ended June 30, 2023. The decrease of $8.3 million or 47% was primarily due to a $10 million upfront license fee due to Pharmosa for the exclusive license in North America to develop and commercialize L606 recorded during the three months ended June 30, 2023. Additionally, there was a $1.4 million decrease in expenses related to our YUTREPIA program driven by expensing prelaunch inventory costs in the prior year. These decreases were offset by a $1.7 million increase in clinical expenses related to our L606 program and a $1.5 million increase in personnel expenses (including stock-based compensation) related to increased headcount.

 

General and administrative expenses were $20.0 million for the three months ended June 30, 2024, compared to $9.2 million for the three months ended June 30, 2023. The increase of $10.8 million or 116% was primarily due to a $6.3 million increase in personnel expenses (including stock-based compensation) driven by higher headcount and expansion of our sales force in the fourth quarter of 2023, a $2.2 million increase in commercial and consulting expenses in preparation for the potential commercialization of YUTREPIA, and a $0.9 million increase in legal fees related to our ongoing YUTREPIA-related litigation.

 

Total other expenses, net was $0.7 million for both the three months ended June 30, 2024 and 2023. There was a $1.2 million increase in interest expenses attributable to the higher borrowings under the company’s Revenue Interest Financing Agreement (RIFA) with HealthCare Royalty Partners (HCRx) as compared to the prior year, and a $1.1 million increase in interest income attributable to higher money market balances.

 

 

 

 

Net loss for the three months ended June 30, 2024, was $27.9 million or $0.37 per basic and diluted share, compared to a net loss of $23.5 million, or $0.36 per basic and diluted share, for the three-month ended June 30, 2023.

 

About YUTREPIA™ (treprostinil) Inhalation Powder

 

YUTREPIA is an investigational, inhaled dry-powder formulation of treprostinil delivered through a convenient, low-effort, palm-sized device. The FDA previously issued tentative approval of YUTREPIA for the PAH indication in November 2021. In July 2023, Liquidia filed an amendment to its New Drug Application for YUTREPIA, seeking to add PH-ILD to the label. YUTREPIA was designed using Liquidia’s PRINT® technology, which enables the development of drug particles that are precise and uniform in size, shape and composition, and that are engineered for enhanced deposition in the lung following oral inhalation. Liquidia has completed INSPIRE, or Investigation of the Safety and Pharmacology of Dry Powder Inhalation of Treprostinil, an open-label, multi-center phase 3 clinical study of YUTREPIA in patients diagnosed with PAH who are naïve to inhaled treprostinil or who are transitioning from Tyvaso® (nebulized treprostinil). YUTREPIA is currently being studied in the ASCENT trial, an Open-Label Prospective Multicenter Study to Evaluate Safety and Tolerability of Dry Powder Inhaled Treprostinil in Pulmonary Hypertension, with the objective of informing YUTREPIA’s dosing and tolerability profile in patients with PH-ILD. YUTREPIA was previously referred to as LIQ861 in investigational studies.

 

About L606 (liposomal treprostinil) Inhalation Suspension

 

L606 is an investigational, sustained-release formulation of treprostinil administered twice-daily with a next-generation nebulizer. The L606 suspension uses Pharmosa Biopharm’s proprietary liposomal formulation to encapsulate treprostinil which can be released slowly at a controlled rate into the lung, enhancing drug exposure over an extended period of time and potentially mitigating local and systemic side effects. L606 is currently being evaluated in an open-label study in the United States for treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD) with a planned global pivotal placebo-controlled efficacy study for the treatment of PH-ILD.

 

About Treprostinil Injection

 

Treprostinil Injection is the first-to-file, fully substitutable generic treprostinil for parenteral administration. Treprostinil Injection contains the same active ingredient, same strengths, same dosage form and same inactive ingredients as Remodulin® (treprostinil) and is offered to patients and physicians with the same level of service and support, but at a lower price than the branded drug. Liquidia PAH promotes the appropriate use of Treprostinil Injection for the treatment of PAH in the United States in partnership with its commercial partner, Sandoz, Inc. (Sandoz), who holds the Abbreviated New Drug Application (ANDA) with the FDA.

 

About Pulmonary Arterial Hypertension (PAH)

 

Pulmonary arterial hypertension (PAH) is a rare, chronic, progressive disease caused by hardening and narrowing of the pulmonary arteries that can lead to right heart failure and eventually death. Currently, an estimated 45,000 patients are diagnosed and treated in the United States. There is currently no cure for PAH, so the goals of existing treatments are to alleviate symptoms, maintain or improve functional class, delay disease progression, and improve quality of life.

 

 

 

 

About Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD)

 

Pulmonary hypertension (PH) associated with interstitial lung disease (ILD) includes a diverse collection of up to 150 different pulmonary diseases, including interstitial pulmonary fibrosis, chronic hypersensitivity pneumonitis, connective tissue disease related ILD, and chronic pulmonary fibrosis with emphysema (CPFE) among others. Any level of PH in ILD patients is associated with poor 3-year survival. A current estimate of PH-ILD prevalence in the United States is greater than 60,000 patients, though population growth in many of these underlying ILD diseases is not yet known due to factors including underdiagnosis and lack of approved treatments until March 2021, when inhaled treprostinil was first approved for this indication.

 

About Liquidia Corporation

 

Liquidia Corporation is a biopharmaceutical company developing innovative therapies for patients with rare cardiopulmonary disease. The company’s current focus spans the development and commercialization of products in pulmonary hypertension and other applications of its proprietary PRINT® Technology. PRINT enabled the creation of Liquidia’s lead candidate, YUTREPIA™ (treprostinil) inhalation powder, an investigational drug for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).  The company is also developing L606, an investigational sustained-release formulation of treprostinil administered twice-daily with a next-generation nebulizer, and currently markets generic Treprostinil Injection for the treatment of PAH. To learn more about Liquidia, please visit www.liquidia.com.

 

Remodulin® and Tyvaso® are registered trademarks of United Therapeutics Corporation.

 

Cautionary Statements Regarding Forward-Looking Statements

 

This press release may include forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release other than statements of historical facts, including statements regarding our future results of operations and financial position, our strategic and financial initiatives, our business strategy and plans and our objectives for future operations, are forward-looking statements. Such forward-looking statements, including statements regarding clinical trials, clinical studies and other clinical work (including the funding therefor, anticipated patient enrollment, safety data, study data, trial outcomes, timing or associated costs), regulatory applications and related submission contents and timelines, including the potential for final FDA approval of the NDA for YUTREPIA, the timeline or outcome related to patent litigation in the U.S. District Court for the District of Delaware or inter partes review proceedings conducted at the PTAB or other litigation instituted by United Therapeutics or others, including rehearings or appeals of decisions in any such proceedings, the issuance of patents by the USPTO and our ability to execute on our strategic or financial initiatives, involve significant risks and uncertainties and actual results could differ materially from those expressed or implied herein. The favorable decisions of courts or other tribunals are not determinative of the outcome of the appeals or rehearings of the decisions. The words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “would,” and similar expressions are intended to identify forward-looking statements. We have based these forward-looking statements largely on our current expectations and projections about future events and financial trends that we believe may affect our financial condition, results of operations, business strategy, short-term and long-term business operations and objectives and financial needs. These forward-looking statements are subject to a number of risks discussed in our filings with the SEC, as well as a number of uncertainties and assumptions. Moreover, we operate in a very competitive and rapidly changing environment and our industry has inherent risks. New risks emerge from time to time. It is not possible for our management to predict all risks, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements we may make. In light of these risks, uncertainties and assumptions, the future events discussed in this press release may not occur and actual results could differ materially and adversely from those anticipated or implied in the forward-looking statements. Nothing in this press release should be regarded as a representation by any person that these goals will be achieved, and we undertake no duty to update our goals or to update or alter any forward-looking statements, whether as a result of new information, future events or otherwise.

 

 

 

 

Contact Information

 

Investors:
Jason Adair
Chief Business Officer
919.328.4350
Jason.adair@liquidia.com

 

Media:
Patrick Wallace
Director, Corporate Communications
919.328.4383
patrick.wallace@liquidia.com

 

Liquidia Corporation
Select Condensed Consolidated Balance Sheet Data (unaudited)
(in thousands)

 

   June 30,   December 31, 
   2024   2023 
Cash and cash equivalents  $133,093   $83,679 
Total assets  $177,361   $118,332 
Total liabilities  $114,639   $71,039 
Accumulated deficit  $(497,968)  $(429,098)
Total stockholders’ equity  $62,722   $47,293 

 

 

 

 

Liquidia Corporation
Condensed Consolidated Statements of Operations and Comprehensive Loss
(unaudited)
(in thousands, except share and per share amounts)

 

   Three Months Ended
June 30,		 
   2024   2023 
Revenue  $3,659   $4,786 
Costs and expenses:          
Cost of revenue   1,493    671 
Research and development   9,420    17,695 
General and administrative   19,943    9,245 
Total costs and expenses   30,856    27,611 
Loss from operations   (27,197)   (22,825)
Other income (expense):          
Interest income   1,855    734 
Interest expense   (2,600)   (1,426)
Total other expense, net   (745)   (692)
Net loss and comprehensive loss  $(27,942)  $(23,517)
Net loss per common share, basic and diluted  $(0.37)  $(0.36)
Weighted average common shares outstanding, basic and diluted   76,435,831    64,788,482 

 

 

 

 EX-101.SCH 3 lqda-20240807.xsd XBRL TAXONOMY EXTENSION SCHEMA 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 4 lqda-20240807_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 5 lqda-20240807_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 7 R1.htm IDEA: XBRL DOCUMENT v3.24.2.u1
Cover
Aug. 07, 2024
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Aug. 07, 2024
Entity File Number 001-39724
Entity Registrant Name LIQUIDIA CORPORATION
Entity Central Index Key 0001819576
Entity Tax Identification Number 85-1710962
Entity Incorporation, State or Country Code DE
Entity Address, Address Line One 419 Davis Drive
Entity Address, Address Line Two Suite 100
Entity Address, City or Town Morrisville
Entity Address, State or Province NC
Entity Address, Postal Zip Code 27560
City Area Code 919
Local Phone Number 328-4400
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common stock
Trading Symbol LQDA
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
EXCEL 8 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 9 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 10 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 12 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.2.u1 html 1 23 1 false 0 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://liquidia.com/role/Cover Cover Cover 1 false false All Reports Book All Reports lqda-20240807.xsd lqda-20240807_lab.xml lqda-20240807_pre.xml tm2420885d1_8k.htm http://xbrl.sec.gov/dei/2023 true false JSON 14 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "tm2420885d1_8k.htm": { "nsprefix": "lqda", "nsuri": "http://liquidia.com/20240807", "dts": { "schema": { "local": [ "lqda-20240807.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd" ] }, "labelLink": { "local": [ "lqda-20240807_lab.xml" ] }, "presentationLink": { "local": [ "lqda-20240807_pre.xml" ] }, "inline": { "local": [ "tm2420885d1_8k.htm" ] } }, "keyStandard": 23, "keyCustom": 0, "axisStandard": 0, "axisCustom": 0, "memberStandard": 0, "memberCustom": 0, "hidden": { "total": 2, "http://xbrl.sec.gov/dei/2023": 2 }, "contextCount": 1, "entityCount": 1, "segmentCount": 0, "elementCount": 59, "unitCount": 3, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 23 }, "report": { "R1": { "role": "http://liquidia.com/role/Cover", "longName": "00000001 - Document - Cover", "shortName": "Cover", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "AsOf2024-08-07", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "p", "body", "html" ], "reportCount": 1, "baseRef": "tm2420885d1_8k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2024-08-07", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "p", "body", "html" ], "reportCount": 1, "baseRef": "tm2420885d1_8k.htm", "first": true, "unique": true } } }, "tag": { "dei_AmendmentDescription": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentDescription", "presentation": [ "http://liquidia.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Description", "documentation": "Description of changes contained within amended document." } } }, "auth_ref": [] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://liquidia.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_AnnualInformationForm": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AnnualInformationForm", "presentation": [ "http://liquidia.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Annual Information Form", "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form." } } }, "auth_ref": [ "r14" ] }, "dei_AuditedAnnualFinancialStatements": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AuditedAnnualFinancialStatements", "presentation": [ "http://liquidia.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Audited Annual Financial Statements", "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements." } } }, "auth_ref": [ "r14" ] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://liquidia.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "dei_CountryRegion": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CountryRegion", "presentation": [ "http://liquidia.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Country Region", "documentation": "Region code of country" } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://liquidia.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "dei_DocumentAccountingStandard": { "xbrltype": "accountingStandardItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAccountingStandard", "presentation": [ "http://liquidia.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Accounting Standard", "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentAnnualReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAnnualReport", "presentation": [ "http://liquidia.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Annual Report", "documentation": "Boolean flag that is true only for a form used as an annual report." } } }, "auth_ref": [ "r11", "r13", "r14" ] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://liquidia.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://liquidia.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://liquidia.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentPeriodStartDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodStartDate", "presentation": [ "http://liquidia.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period Start Date", "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format." } } }, "auth_ref": [] }, "dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentQuarterlyReport", "presentation": [ "http://liquidia.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report." } } }, "auth_ref": [ "r12" ] }, "dei_DocumentRegistrationStatement": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentRegistrationStatement", "presentation": [ "http://liquidia.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Registration Statement", "documentation": "Boolean flag that is true only for a form used as a registration statement." } } }, "auth_ref": [ "r0" ] }, "dei_DocumentShellCompanyEventDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentShellCompanyEventDate", "presentation": [ "http://liquidia.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Event Date", "documentation": "Date of event requiring a shell company report." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentShellCompanyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentShellCompanyReport", "presentation": [ "http://liquidia.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Report", "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentTransitionReport", "presentation": [ "http://liquidia.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": [ "r15" ] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://liquidia.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentsIncorporatedByReferenceTextBlock", "presentation": [ "http://liquidia.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Documents Incorporated by Reference [Text Block]", "documentation": "Documents incorporated by reference." } } }, "auth_ref": [ "r3" ] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://liquidia.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine2", "presentation": [ "http://liquidia.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine3": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine3", "presentation": [ "http://liquidia.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Three", "documentation": "Address Line 3 such as an Office Park" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://liquidia.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressCountry": { "xbrltype": "countryCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCountry", "presentation": [ "http://liquidia.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Country", "documentation": "ISO 3166-1 alpha-2 country code." } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://liquidia.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://liquidia.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityBankruptcyProceedingsReportingCurrent", "presentation": [ "http://liquidia.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Bankruptcy Proceedings, Reporting Current", "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element." } } }, "auth_ref": [ "r6" ] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://liquidia.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r2" ] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCommonStockSharesOutstanding", "presentation": [ "http://liquidia.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCurrentReportingStatus", "presentation": [ "http://liquidia.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://liquidia.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r2" ] }, "dei_EntityExTransitionPeriod": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityExTransitionPeriod", "presentation": [ "http://liquidia.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Elected Not To Use the Extended Transition Period", "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards." } } }, "auth_ref": [ "r19" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://liquidia.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFilerCategory", "presentation": [ "http://liquidia.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [ "r2" ] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://liquidia.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityInteractiveDataCurrent", "presentation": [ "http://liquidia.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": [ "r16" ] }, "dei_EntityPrimarySicNumber": { "xbrltype": "sicNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPrimarySicNumber", "presentation": [ "http://liquidia.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Primary SIC Number", "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity." } } }, "auth_ref": [ "r14" ] }, "dei_EntityPublicFloat": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPublicFloat", "crdr": "credit", "presentation": [ "http://liquidia.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Public Float", "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://liquidia.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r2" ] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityShellCompany", "presentation": [ "http://liquidia.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": [ "r2" ] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntitySmallBusiness", "presentation": [ "http://liquidia.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": [ "r2" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://liquidia.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r2" ] }, "dei_EntityVoluntaryFilers": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityVoluntaryFilers", "presentation": [ "http://liquidia.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Voluntary Filers", "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act." } } }, "auth_ref": [] }, "dei_EntityWellKnownSeasonedIssuer": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityWellKnownSeasonedIssuer", "presentation": [ "http://liquidia.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Well-known Seasoned Issuer", "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A." } } }, "auth_ref": [ "r17" ] }, "dei_Extension": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Extension", "presentation": [ "http://liquidia.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Extension", "documentation": "Extension number for local phone number." } } }, "auth_ref": [] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://liquidia.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_NoTradingSymbolFlag": { "xbrltype": "trueItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "NoTradingSymbolFlag", "presentation": [ "http://liquidia.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "No Trading Symbol Flag", "documentation": "Boolean flag that is true only for a security having no trading symbol." } } }, "auth_ref": [] }, "dei_OtherReportingStandardItemNumber": { "xbrltype": "otherReportingStandardItemNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "OtherReportingStandardItemNumber", "presentation": [ "http://liquidia.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Other Reporting Standard Item Number", "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS." } } }, "auth_ref": [ "r13" ] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://liquidia.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r7" ] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementTenderOffer", "presentation": [ "http://liquidia.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r8" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://liquidia.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r1" ] }, "dei_Security12gTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12gTitle", "presentation": [ "http://liquidia.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(g) Security", "documentation": "Title of a 12(g) registered security." } } }, "auth_ref": [ "r5" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://liquidia.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r4" ] }, "dei_SecurityReportingObligation": { "xbrltype": "securityReportingObligationItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityReportingObligation", "presentation": [ "http://liquidia.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Reporting Obligation", "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act." } } }, "auth_ref": [ "r9" ] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SolicitingMaterial", "presentation": [ "http://liquidia.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r10" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://liquidia.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "WrittenCommunications", "presentation": [ "http://liquidia.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r18" ] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-23" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "g" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12, 13, 15d" }, "r7": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r8": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r9": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "15", "Subsection": "d" }, "r10": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Section": "14a", "Number": "240", "Subsection": "12" }, "r11": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-K", "Number": "249", "Section": "310" }, "r12": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-Q", "Number": "240", "Section": "308", "Subsection": "a" }, "r13": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Number": "249", "Section": "220", "Subsection": "f" }, "r14": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Number": "249", "Section": "240", "Subsection": "f" }, "r15": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r16": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r17": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "405" }, "r18": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" }, "r19": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "7A", "Section": "B", "Subsection": "2" } } } ZIP 15 0001104659-24-086529-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001104659-24-086529-xbrl.zip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end XML 16 tm2420885d1_8k_htm.xml IDEA: XBRL DOCUMENT 0001819576 2024-08-07 2024-08-07 iso4217:USD shares iso4217:USD shares false 0001819576 8-K 2024-08-07 LIQUIDIA CORPORATION DE 001-39724 85-1710962 419 Davis Drive Suite 100 Morrisville NC 27560 919 328-4400 false false false false Common stock LQDA NASDAQ false